Category: Blood Test

Ovarian cancer is diagnosed in around 7,000 women in the UK every year — approximately 20 women every single day. It is the sixth most common cancer in women, and one of the hardest to catch early. The symptoms it produces — bloating, abdominal discomfort, a persistent feeling of fullness, changes in urinary frequency — are vague enough to overlap with a range of far more common and benign conditions, which means diagnosis is frequently delayed. Against this backdrop, the question of whether a blood test can show ovarian cancer is one of the most important questions a woman can ask. The answer is nuanced, honest, and — thanks to significant recent developments in UK clinical guidance — more useful than it has ever been.

The CA125 Blood Test: What It Is and What It Can Tell You

The primary blood test used in the assessment of suspected ovarian cancer in the UK is the CA125 test. CA125 — cancer antigen 125 — is a protein found in the blood that can be elevated in the presence of ovarian cancer. According to Cancer Research UK, CA125 is raised in more than 80% of advanced ovarian cancers and in around 50% of early-stage cases. It is available at GP surgeries across England and is the first-line blood investigation recommended by NICE for women with symptoms suggesting ovarian cancer.

According to Target Ovarian Cancer, a normal CA125 level is usually considered to be below 35 units per millilitre (u/ml). If your level is at 35 u/ml or above, your GP should arrange an urgent pelvic ultrasound scan to look at your ovaries and assess whether any abnormality is present.

It is important to understand what this test does and does not tell you. A raised CA125 is not a diagnosis of ovarian cancer — not by a considerable distance. The elevated protein level indicates inflammation around the pelvis, but it cannot identify the cause. It can be raised in a wide range of conditions that have nothing to do with cancer, including endometriosis, uterine fibroids, ovarian cysts, pelvic inflammatory disease, liver disease, and even menstruation. Being pregnant can also raise CA125 levels. According to Ovarian Cancer Action, nine in ten women with a raised CA125 will not have ovarian cancer.

The converse limitation is equally important: a normal CA125 result does not rule out ovarian cancer. Some women — particularly those with early-stage disease or with certain less common subtypes of ovarian cancer — may have entirely normal CA125 levels despite a cancer being present. Ovarian Cancer Action states explicitly that CA125 levels can be normal in the early stages of ovarian cancer, and that if symptoms persist after a normal result, a woman should return to her GP within a month to discuss whether an ultrasound is needed regardless.

A Significant Step Forward: NICE’s New Age-Based CA125 Thresholds

One of the most clinically important recent developments in this area comes from NICE — the National Institute for Health and Care Excellence — which in 2024–25 proposed a significant update to how CA125 results are interpreted. Currently, a single threshold of 35 IU/ml applies to all women regardless of age. NICE’s updated draft guidance proposes replacing this with personalised, age-based thresholds that reflect how ovarian cancer risk changes as women get older.

According to NICE, the aim of this change is to ensure that women at the greatest risk of ovarian cancer are identified and referred sooner, while reducing unnecessary investigations for women at lower risk. The new approach would allow GPs to make more informed, individualised decisions — using a woman’s age alongside her CA125 level to assess her actual risk profile, rather than applying a blanket threshold. The updated guideline also proposes that women aged 60 and over with unexplained weight loss of more than 5% over six months should receive an urgent investigation or suspected cancer pathway referral, reflecting the higher baseline risk in this age group.

For women and their GPs, this represents a meaningful shift towards more targeted and clinically intelligent use of the CA125 test — and signals clearly that the conversation about CA125 is evolving, not static.

A Larger Study Confirms CA125’s Value — With Important Caveats

A large NIHR-funded study, published in 2024 and analysing data from over 50,000 women who had taken a CA125 test at their GP surgery, found that the test performed considerably better at predicting ovarian cancer in primary care than was previously appreciated. The research, which arose from the Cancer Research UK-funded CanTest Collaborative, found that the test was particularly effective in women aged over 50 — in whom ovarian cancer is most common — and also identified that a raised CA125 in a woman over 50 in whom ovarian cancer has been excluded should prompt investigation for other cancers, including those of the pancreas and lung.

The researchers developed a model to estimate an individual woman’s probability of ovarian cancer based on her age and CA125 result — a more nuanced, personalised risk tool than the current binary threshold approach. While this model is not yet in routine clinical use, it signals clearly where the UK diagnostic pathway for ovarian cancer is heading: towards individualised, risk-stratified assessment rather than a one-size-fits-all approach.

A patient seen at our Birmingham clinic — a woman in her early fifties — presented with several weeks of persistent bloating and a sensation of abdominal fullness that she had attributed to dietary changes. A private blood test including CA125 revealed a level of 58 u/ml. She was referred promptly for an urgent pelvic ultrasound, which identified a suspicious ovarian mass requiring specialist assessment. Early identification at this stage gave her access to treatment options that would not have been available had her symptoms been dismissed for another several months.

Additional Blood Tests Used in Ovarian Cancer Assessment

CA125 is the primary blood marker, but it is not the only one. Depending on clinical circumstances — particularly a woman’s age and the nature of her symptoms — a GP or specialist may also request:

HE4 and the ROMA Algorithm

Human epididymis protein 4 (HE4) is a newer tumour marker that has been shown to be elevated in ovarian cancer. Research funded by Wellbeing of Women and carried out by Dr Garth Funston at the University of Manchester — examining blood samples from 1,247 patients — found that HE4 levels, when combined with CA125 within an algorithm called ROMA (Risk of Ovarian Malignancy Algorithm), could improve the detection of ovarian cancer in primary care, particularly in women under 50. The ROMA algorithm uses both markers alongside menopausal status to generate a risk score — offering a more accurate picture than CA125 alone in certain groups. This approach has been studied in hospital settings for some time, but Wellbeing of Women’s research is among the first to demonstrate its utility in a primary care environment.

AFP, hCG, and LDH for Younger Women

For women aged 40 and under, Cancer Research UK notes that specialists may also check the levels of alpha-fetoprotein (AFP), human chorionic gonadotrophin (hCG), and lactate dehydrogenase (LDH). These markers are associated with germ cell tumours — a rarer type of ovarian cancer more commonly seen in younger women — and form part of the extended assessment for this age group.

CEA and CA19-9

According to Cancer Research UK’s diagnostic guidance, specialists may also measure CEA (carcinoembryonic antigen) and CA19-9 in certain cases — particularly where there is a possibility that another cancer type has spread to the ovaries, rather than the tumour originating there. These markers help build a more complete picture of what is driving any ovarian abnormality found on imaging.

What About the UKCTOCS Screening Trial?

The UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) was a large long-term study that investigated whether CA125 testing — either alone or combined with ultrasound — could serve as a general population screening tool for ovarian cancer. The trial’s conclusions, reported by Cancer Research UK, were sobering: while the CA125 blood test did detect some cancers earlier, this earlier detection did not translate into a statistically significant saving of lives. Ultrasound screening also failed to reduce mortality. On the basis of these findings, neither test is recommended as a routine screening tool for the general population in the UK.

This does not mean CA125 is without value — it means it is best used as a diagnostic investigation in women with symptoms, not as a general screening test in asymptomatic women. The distinction matters enormously, both for clinical practice and for understanding what to expect when a GP requests this test.

Symptoms That Should Prompt a CA125 Blood Test

According to NICE clinical guidelines, a CA125 blood test should be offered to any woman — particularly those aged 50 or over — who presents with any of the following symptoms, especially if they are frequent, persistent, or new:

• Persistent abdominal bloating, particularly if it comes on most days
• A feeling of fullness or difficulty eating normally, even when eating smaller amounts than usual
• Pelvic or abdominal pain that is new or unexPlained
• Needing to urinate more urgently or more frequently than usual
• Unexplained weight loss
• Changes in bowel habit — particularly new constipation — that have no other clear explanation
• Extreme fatigue without a clear cause
• Postmenopausal bleeding

It is worth emphasising what Target Ovarian Cancer and NICE guidance both make clear: if your CA125 result comes back normal but your symptoms persist, you should return to your GP within a month and discuss whether a pelvic ultrasound is warranted regardless. Symptoms, not test results alone, should drive the clinical decision-making process in suspected ovarian cancer.

At The Private GP in Birmingham, a face-to-face GP consultation gives you direct access to a GMC-registered doctor who will take your symptoms seriously, arrange a CA125 blood test with same-day results, and refer promptly for urgent ultrasound where the clinical picture warrants it. You do not need to wait weeks for an NHS appointment when concerns like these deserve prompt attention. Book today.

If You Have a Family History or BRCA Gene Mutation

Women with a BRCA1 or BRCA2 gene mutation, or a strong family history of ovarian or breast cancer, face a significantly elevated lifetime risk of ovarian cancer and may be offered more intensive surveillance — including six-monthly CA125 tests and pelvic ultrasounds — through specialist family history clinics. The NICE 2024 guideline on identifying and managing familial and genetic risk of ovarian cancer provides detailed guidance on this pathway. If you have a relevant family history and have not yet been assessed for your genetic risk, discussing this with your GP is an important step. A private GP consultation can facilitate prompt referral to a clinical genetics service where appropriate.

Frequently Asked Questions

• What does a raised CA125 mean?

A CA125 above 35 u/ml means the level of the CA125 protein in your blood is higher than the normal range. According to Target Ovarian Cancer and NICE guidelines, this should prompt your GP to arrange an urgent pelvic ultrasound scan. However, a raised CA125 does not mean you have ovarian cancer — nine in ten women with a raised result will not have cancer, and elevated CA125 can be caused by many benign conditions including endometriosis, fibroids, ovarian cysts, and pelvic inflammatory disease. It is a prompt for investigation, not a diagnosis.

• Can a blood test rule out ovarian cancer?

No blood test can definitively rule out ovarian cancer. A normal CA125 result provides some reassurance, but it does not exclude the diagnosis — particularly at an early stage or in less common tumour types where CA125 may remain within the normal range. According to Ovarian Cancer Action, if your symptoms persist after a normal CA125 result, you should return to your GP within a month to discuss whether a pelvic ultrasound is still needed. Symptoms must drive clinical decision-making alongside test results.

• What is the difference between CA125 and HE4?

CA125 and HE4 are both tumour markers associated with ovarian cancer. CA125 is the established first-line test in UK primary care. HE4 is a newer marker that, when combined with CA125 within the ROMA algorithm, has been shown to improve detection accuracy — particularly in women under 50, where CA125 alone is less reliable due to benign conditions that commonly elevate it. HE4-based testing is not yet in routine use at UK GP surgeries, but research funded by Wellbeing of Women suggests it may enter the primary care diagnostic pathway in the future.

• Is there a screening test for ovarian cancer in the UK?

There is currently no national ovarian cancer screening programme in the UK for the general population. The UKCTOCS trial, which evaluated CA125 blood testing and ultrasound as screening tools, found that while CA125 detected some cancers earlier, this did not translate into a significant reduction in deaths — and the tests were not recommended for routine screening. Women at high genetic risk (BRCA1/2 mutation or strong family history) are offered surveillance through specialist clinics. Any woman with persistent symptoms should seek a GP assessment and request a CA125 blood test. At The Private GP, a private blood test in Birmingham including CA125 is available with same-day results.

• How long does a CA125 blood test take to get results?

At The Private GP in Birmingham, CA125 blood test results are typically available the same day, with a GMC-registered GP on hand to interpret what the result means for you specifically — including whether further investigation is needed and how urgently. If you are having a CA125 test through your NHS GP, your surgery will advise on turnaround time, which is typically within one to two weeks. If you do not hear within two weeks, Target Ovarian Cancer advises calling your GP to follow up. You can also register for online access to your medical record through your GP surgery or the NHS app.

Mounjaro — the brand name for tirzepatide — has become one of the most talked-about medications in the UK since NICE recommended it for weight management in December 2024. Whether you are already using it, considering it, or simply curious about how it interacts with routine healthcare, the question comes up regularly: does Mounjaro show up on a blood test? People ask for different reasons — some want to understand their monitoring requirements, others are concerned about privacy, and some have simply had a blood test come back with unexpected results and want to make sense of what Mounjaro might have to do with it.

The answer has two parts, and both matter. Mounjaro itself is invisible to routine blood testing — but its effects on your body are thoroughly measurable, clinically significant, and worth monitoring carefully.

Mounjaro Does Not Appear on Standard Blood Tests

Let us be direct on the most commonly asked version of this question: Mounjaro (tirzepatide) is not detected by any routine blood test used in standard UK clinical practice. A full blood count, liver function tests, kidney function tests, HbA1c, lipid panel, thyroid function tests, and inflammatory markers — none of these tests will flag Mounjaro as a substance in your bloodstream.

Standard clinical blood tests measure physiological markers — the levels of proteins, enzymes, hormones, blood cells, and metabolic byproducts that reflect how your body is functioning. They are not designed to identify specific medications, and Mounjaro, as a peptide-based injectable, does not appear in any of these panels. Multiple patients who have had routine blood tests while on Mounjaro — including NHS annual reviews and private health checks — confirm that no test result specifically flags or identifies the medication.

Mounjaro is also not included in standard drug screening panels — the kind used for employment, insurance, or other purposes — which focus on controlled substances and drugs of abuse.

What Mounjaro Does to Your Blood Results

While Mounjaro itself remains undetectable, it has a meaningful and measurable impact on several key blood markers. In fact, one of the most rewarding aspects of Mounjaro treatment for many patients is seeing these markers improve over successive tests. Understanding which markers change — and what those changes mean — helps you make the most of your monitoring and gives you and your GP the clearest possible picture of how treatment is progressing.

HbA1c and Blood Glucose

Mounjaro works by mimicking two gut hormones — GLP-1 and GIP — that regulate insulin secretion and glucose metabolism. Its most direct blood test effect is a reduction in blood glucose and, over time, HbA1c — the marker that reflects average blood sugar control over approximately three months. For people using Mounjaro to manage type 2 diabetes, a falling HbA1c is the primary measure of treatment effectiveness. For those using it for weight management without diabetes, a reducing HbA1c indicates improving metabolic health, reduced insulin resistance, and a lower risk of developing type 2 diabetes in the future. An HbA1c blood test is therefore central to monitoring anyone on Mounjaro, typically repeated every three months during the initial period of treatment.

Cholesterol and Lipids

Clinical trial data from the SURMOUNT programme — the international trials that formed the basis of Mounjaro’s weight management approval — demonstrated consistent improvements in lipid profiles among participants. Total cholesterol, LDL (the variety associated with cardiovascular risk), and triglycerides all fell meaningfully, while HDL cholesterol — the protective variety — tended to rise. Many patients on Mounjaro find that previously elevated cholesterol levels move into the normal range without any change to statin therapy — and some find that their cholesterol medication can be reviewed and adjusted as a result. Regular cholesterol testing gives you an objective picture of this cardiovascular improvement over time.

Liver Function

Mounjaro can produce notable improvements in liver function markers, particularly in people who had mildly elevated enzymes before treatment — which is common in those with non-alcoholic fatty liver disease (NAFLD), a condition closely linked to obesity and insulin resistance. As weight reduces and liver fat decreases, ALT levels often fall towards the normal range. However, a mild transient rise in liver enzymes can also occur in some patients early in treatment or during periods of rapid weight loss — a pattern that real-world UK patients have reported in online communities and that their GPs have monitored and confirmed as self-resolving. Liver function should be assessed at baseline and monitored during treatment, particularly in anyone with pre-existing liver conditions.

Kidney Function

Kidney function markers — creatinine, urea, and eGFR — are included in the recommended baseline assessment before starting Mounjaro, and should be monitored during treatment. Mounjaro, like other GLP-1 receptor agonists, can in rare cases contribute to kidney stress — most commonly through dehydration caused by nausea and vomiting in the early weeks of treatment. Ensuring adequate fluid intake, particularly during dose escalation, reduces this risk considerably. An eGFR blood test provides a clear and specific measure of kidney filtration capacity and is a sensible component of any Mounjaro monitoring panel.

Pancreatic Enzymes: Amylase and Lipase

Pancreatitis is a recognised — if uncommon — risk associated with GLP-1 receptor agonists, and Mounjaro is no exception. Amylase and lipase — the primary pancreatic enzymes — are worth monitoring during Mounjaro treatment, particularly if you experience persistent abdominal pain, nausea, or vomiting that does not settle with the usual management strategies. Mild asymptomatic elevations in these enzymes can occur without clinical pancreatitis, but significant or symptomatic rises warrant prompt GP assessment. Anyone with a prior history of pancreatitis should not take Mounjaro.

Nutritional Markers

Mounjaro’s appetite-suppressing effects can reduce overall food intake substantially, particularly at higher doses. For most people this is the intended outcome — but it can also lead to nutritional deficiencies if dietary quality is not maintained alongside the reduction in quantity. Real-world UK patient reports and clinical monitoring data have identified folate, vitamin B12, vitamin D, and iron as the markers most commonly affected. Fatigue, hair changes, or mood shifts while on Mounjaro may reflect a nutritional deficiency rather than a direct medication effect — and are well worth investigating with a blood test. A private blood test that includes these nutritional markers alongside the standard metabolic panel gives the most comprehensive picture of how your body is responding to treatment.

A patient seen at our Birmingham clinic — a woman in her mid-forties who had been on Mounjaro for approximately five months — came in reporting persistent fatigue and increased hair shedding despite good weight loss progress. A comprehensive monitoring blood test identified low-normal ferritin and borderline vitamin B12 — findings consistent with reduced dietary intake alongside successful weight loss. Targeted nutritional support resolved her symptoms within eight weeks, and her weight loss journey continued without interruption.

The Blood Tests You Should Have Before Starting Mounjaro

Whether you are accessing Mounjaro through the NHS or privately, a set of baseline blood tests is an important and clinically appropriate step before beginning treatment. These tests serve three purposes: they establish a reference point for monitoring treatment effects, they identify any pre-existing conditions that might affect eligibility or require additional care, and they provide the clinical context needed to interpret any changes that emerge during treatment.

A thorough pre-Mounjaro blood panel should include:

• HbA1c and fasting glucose: To confirm glycaemic baseline and establish a reference for monitoring treatment effect on blood sugar.
• Kidney function (creatinine, urea, eGFR): To confirm adequate kidney function before initiation and provide a baseline for ongoing monitoring.
• Liver function (ALT, AST, ALP, bilirubin): To assess baseline liver health, particularly in those with obesity-related liver conditions.
• Lipid profile: To assess cardiovascular risk and track metabolic improvement over the course of treatment.
• Full blood count: To screen for anaemia and assess general health.
• Thyroid function (TSH): To screen for any contraindicated thyroid conditions and establish a hormonal baseline.
• Nutritional markers (B12, folate, vitamin D, ferritin): To identify any pre-existing deficiencies that may worsen with reduced appetite.

At The Private GP in Birmingham, we offer comprehensive private blood testing covering all of these baseline markers, with same-day results and clinical interpretation by a GMC-registered GP. Whether you are preparing to start Mounjaro, reviewing your progress during treatment, or concerned about a specific result, we can provide the thorough, personalised assessment your care deserves — without the wait.

How Often Should You Have Blood Tests on Mounjaro?

Monitoring frequency during Mounjaro treatment should be tailored to your individual circumstances — your baseline health, whether you are using the medication for weight management or diabetes, the presence of any side effects, and how your results evolve over time. As a general guide, most clinical providers recommend:

• Before starting: A full baseline panel as described above.
• At 3 months: HbA1c, kidney and liver function, lipids, and full blood count — to assess early response and monitor for any emerging issues during the dose escalation phase.
• Every 6 months thereafter: Repeat of the key metabolic markers alongside a clinical review of weight, blood pressure, and any side effects.
• At any point if symptoms arise: Persistent abdominal pain, fatigue, hair changes, dizziness, or reduced urine output are all reasons to arrange a blood test promptly rather than waiting for a scheduled review.

At The Private GP, our GMC-registered doctors provide personalised Mounjaro monitoring as part of our weight loss services — taking into account your full clinical picture and ensuring that blood testing is timed and interpreted in a way that genuinely supports your treatment journey. Same-day appointments are available. Book today.

Does Mounjaro Show Up on a Drug Test?

No. Mounjaro is not included in any standard drug screening panel used for employment, insurance, or legal purposes. Standard drug tests screen for controlled substances and drugs of abuse — opioids, benzodiazepines, cannabis, cocaine, and similar compounds. Mounjaro is a medication for weight management and type 2 diabetes and does not fall into any of these categories. Its use will not cause a positive result on any routine drug screening test.

For competitive athletes subject to anti-doping regulations, the World Anti-Doping Agency (WADA) prohibited list does not currently include Mounjaro or other GLP-1/GIP receptor agonists, though this is an area of evolving discussion in sports medicine. If you are subject to specific anti-doping obligations, verifying your medication against the current prohibited list directly is always advisable.

Frequently Asked Questions

• Will a GP know I am on Mounjaro from my blood test results?

Not directly — Mounjaro itself does not appear in blood test results. However, its metabolic effects are measurable: falling HbA1c and blood glucose, an improving lipid profile, and potentially changing liver markers are all consistent with Mounjaro use. A GP who is aware you are on Mounjaro will be better placed to interpret these changes accurately. If your Mounjaro use is on your NHS record, your GP will likely already be aware — but always disclose it proactively to any clinician reviewing your blood results, particularly if you have accessed the medication privately.

• Should I tell my GP I am taking Mounjaro before having a blood test?

Yes — always. While Mounjaro does not directly interfere with blood test measurements, it produces changes in HbA1c, liver enzymes, and kidney function that need to be interpreted in the context of your treatment. A clinician who does not know you are on Mounjaro may misread a falling HbA1c as hypoglycaemia risk, flag an improving liver result as unexpected, or miss early signs of a side effect that would be immediately recognisable with the medication in mind. Transparency about all medications is always the right clinical approach.

• What should I do if my blood test results change while on Mounjaro?

Changes in blood results while on Mounjaro should always be reviewed in the context of your treatment. Improving markers — falling HbA1c, better cholesterol — are expected and welcome. Concerning changes — rising liver enzymes, declining kidney function, elevated pancreatic markers — warrant prompt clinical assessment rather than monitoring at home. A private GP consultation at The Private GP in Birmingham offers same-day appointments where your results can be reviewed and any necessary action taken without delay.

• Can Mounjaro cause a false positive on any blood test?

No. Mounjaro does not interfere with standard laboratory assay methodologies and does not cause false positive results on any routine blood test panel. Mild elevations in liver enzymes or pancreatic markers can occur in some patients during treatment, but these reflect genuine physiological changes rather than laboratory interference — and they are meaningful clinical findings to discuss with your GP, not erroneous results to dismiss.

• Is there a specific Mounjaro blood test I should have?

There is no single bespoke Mounjaro test — rather, effective monitoring involves a combination of standard clinical markers assessed at appropriate intervals. A comprehensive panel covering HbA1c, kidney function, liver function, lipid profile, full blood count, and nutritional markers (B12, folate, vitamin D, ferritin) gives the most complete picture of both treatment effectiveness and safety. At The Private GP, a private blood test in Birmingham can be tailored to your Mounjaro monitoring needs, with same-day results and full GP interpretation.

Appendicitis is the most common reason for emergency abdominal surgery in the world — and in the UK, appendectomies are among the most frequently performed operations. When the pain strikes, understanding what investigations can and cannot tell you becomes urgently relevant. Will a blood test show appendicitis? The honest, clinically accurate answer is this: a blood test cannot diagnose appendicitis on its own, but it plays an important and well-established role in the diagnostic process — helping clinicians assess the likelihood of appendicitis, judge its severity, and guide decisions about imaging and surgery. Knowing what the blood tests look for — and where their limitations lie — can help you make sense of what is happening when you or someone you care about is being assessed.

Why Appendicitis Cannot Be Diagnosed by Blood Test Alone

Appendicitis occurs when the appendix — a small, finger-shaped pouch attached to the large intestine in the lower right abdomen — becomes blocked, inflamed, and infected. Left untreated, it can rupture, releasing bacteria into the abdominal cavity and causing peritonitis, abscess formation, or sepsis — all of which are life-threatening. Speed of diagnosis is therefore critical.

The challenge is that no single blood test, urine test, or imaging study can definitively confirm or exclude appendicitis in all cases. A systematic review published in ScienceDirect, analysing fifty-eight studies on appendicitis diagnosis, noted that clinical signs or positive blood results can be absent in up to 55% of patients — and that the reported rate of missed diagnosis ranges between 20% and 40%. This is not a reflection of clinical inadequacy; it is the nature of a condition that can present in highly variable ways, particularly in children, older adults, pregnant women, and those whose appendix sits in an unusual anatomical position.

Blood tests are therefore used as one strand of a multi-component assessment — alongside clinical history, physical examination, scoring systems such as the Alvarado score, and imaging — rather than as a standalone diagnostic tool.

The Key Blood Markers Used in Appendicitis Assessment

White Blood Cell Count (WBC)

The white blood cell count is the most widely used blood marker in suspected appendicitis, and for good reason. When the body is fighting an infection or dealing with significant inflammation, white blood cell production increases — and the appendix, when inflamed, produces a pronounced inflammatory response. Studies consistently show that around 80 to 85% of adults with confirmed appendicitis have a white blood cell count above 10,500 cells per microlitre. A rise in neutrophils — the specific white blood cell type that surges during bacterial infection — is particularly significant, with neutrophilia greater than 75% occurring in around 78% of confirmed appendicitis cases.

However — and this is clinically important — fewer than 4% of people with appendicitis have both a normal white blood cell count and normal neutrophil levels simultaneously. This means that a normal WBC with normal neutrophils makes appendicitis considerably less likely, even if it cannot rule it out entirely. Conversely, a raised WBC alone is not specific to appendicitis at all: it can be elevated in any inflammatory or infectious condition, from a urinary tract infection to pneumonia.

C-Reactive Protein (CRP)

CRP is an acute-phase protein produced by the liver in response to inflammation. It rises more slowly than the white blood cell count — typically beginning to increase within the first twelve hours of symptom onset — which means it can appear normal in very early appendicitis. A systematic review published in ScienceDirect found that the diagnostic accuracy of CRP improves considerably over time: on day one of confirmed appendicitis, the area under the curve (AUC) for CRP was 0.60 — modest predictive value. By day two, this rose to 0.77, and by day three to 0.88 — considerably more informative.

Strikingly, very high CRP levels in the context of appendicitis are clinically meaningful in a different way: they suggest the appendix may already have perforated or become gangrenous. A PubMed study of 897 patients found that the median CRP level in those with ruptured appendicitis was substantially higher than in those with a normal appendix — making CRP useful not just for detecting appendicitis, but for gauging its severity and the urgency of surgical intervention.

Neutrophil Count in Isolation

Research published in PMC (Cureus) — reviewing all appendectomies performed at one centre over a calendar year alongside their admission blood results and histological outcomes — found that of the three markers examined, the neutrophil count was the most sensitive individual marker for histologically confirmed appendicitis, with a sensitivity of 82%. CRP was the most specific, at 75%. Crucially, when all three markers — WBC, neutrophil count, and CRP — were combined and any single abnormality was used as a positive result, the sensitivity for detecting confirmed appendicitis rose to 96%. This means that if all three results are simultaneously normal, appendicitis is highly unlikely — though if clinical suspicion persists, imaging or further evaluation should still be pursued.

What Blood Tests Cannot Tell You

Understanding the limitations of blood testing in appendicitis is just as important as understanding what the tests can reveal:

A Normal Blood Test does not rule out Appendicitis

As the ScienceDirect systematic review noted, clinical signs and positive blood results can be absent in more than half of patients. Early-stage appendicitis — particularly in the first twelve hours of symptom onset — may not yet have produced a measurable inflammatory response in the blood.

Elevated Markers are not Specific to Appendicitis

A raised WBC and CRP can be produced by almost any infection or inflammatory condition — a urinary tract infection, pelvic inflammatory disease, ovarian cyst, Crohn’s disease flare, or even a chest infection. The blood test tells you that inflammation is present; it cannot pinpoint where it is coming from.

Blood Tests are Unreliable in Certain Groups

In pregnant women, the physiological increase in white blood cells during pregnancy makes WBC interpretation particularly difficult. In infants and older adults, the expected inflammatory response may be blunted — meaning these patients can have confirmed appendicitis with entirely normal or only mildly elevated blood markers. In these populations, clinical assessment and imaging are especially important.

What Other Tests Are Used Alongside Blood Tests?

Because blood tests alone cannot confirm or exclude appendicitis, they are used as part of a broader diagnostic pathway that typically includes:

Urine Test

A urine test is performed early in the assessment to rule out a urinary tract infection or kidney stones — both of which can produce right-sided abdominal or flank pain closely mimicking appendicitis. It is worth noting that a urine test is not always straightforward in the context of appendicitis: a study of 500 patients with confirmed appendicitis found that one in seven had pyuria (white blood cells in the urine), and one in six had blood in the urine — findings that can be caused by irritation of the ureter by an inflamed appendix lying close to it. Appendicitis should therefore not be dismissed because of an abnormal urine result.

Pregnancy Test

For women of childbearing age, a pregnancy test — either blood or urine — is an essential part of the assessment. Ectopic pregnancy can produce severe right-sided pain, and CT scanning — the most accurate imaging investigation for appendicitis — carries radiation exposure that would be avoided or minimised in early pregnancy. Confirming or excluding pregnancy is therefore a priority before imaging decisions are made.

Imaging: CT, Ultrasound, and MRI

Where clinical assessment and blood results do not provide a clear answer, imaging is the most definitive next step. A CT scan of the abdomen and pelvis is the most accurate imaging method for confirming appendicitis in adults — it can clearly visualise the appendix, identify signs of inflammation, perforation, or abscess formation, and assess for alternative diagnoses. Ultrasound is often used in children and pregnant women due to the absence of radiation exposure; while less sensitive than CT, it can frequently identify an inflamed appendix. MRI, while radiation-free, is less commonly available as a first-line investigation but is increasingly used where CT is to be avoided. At The Private GP, we can facilitate an urgent MRI or CT referral where imaging is needed to support the diagnostic process.

Clinical Scoring Systems

The Alvarado score is one of the most widely used clinical decision tools in suspected appendicitis. It combines symptoms (nausea/vomiting, migration of pain to the right iliac fossa, anorexia), clinical signs (rebound tenderness, raised temperature), and blood markers (elevated white blood cell count, neutrophilia) into a numerical score that stratifies patients by likelihood of appendicitis. A high Alvarado score alongside raised blood inflammatory markers significantly increases clinical suspicion and the urgency of imaging and surgical review.

Symptoms That Require Emergency Assessment

Appendicitis is a medical emergency. If you or someone around you has any of the following symptoms, seek emergency medical care immediately — do not wait for a GP appointment or blood test results:

• Sudden, severe abdominal pain that begins around the navel and migrates to the lower right side of the abdomen within hours
• Pain that worsens with movement, coughing, or pressing on the lower right abdomen
• Nausea and vomiting alongside abdominal pain
• Fever — even a low-grade temperature alongside abdominal pain warrants urgent assessment
• Loss of appetite combined with significant abdominal discomfort
• A rigid or board-like abdomen — which can indicate perforation and peritonitis, requiring immediate emergency care

It is important to know that appendicitis does not always present in the classic way — particularly in children, older adults, pregnant women, and those with an atypical appendix position. If you have significant abdominal pain that you cannot explain and that is worsening, always err on the side of seeking emergency assessment rather than waiting.

If your symptoms are less acute but persistent — or if you have had abdominal pain that has resolved but keeps returning and has not been properly investigated — a face-to-face GP consultation at The Private GP in Birmingham allows you to have a thorough clinical assessment, same-day blood testing, and prompt referral for imaging where appropriate. Our GMC-registered doctors take abdominal symptoms seriously and will not leave you without answers.

What a Private Blood Test Can Offer

While a blood test cannot diagnose appendicitis on its own, a private blood test in Birmingham that includes a full blood count, CRP, and a comprehensive metabolic panel provides the same-day inflammatory markers that form a central part of the appendicitis assessment in hospital emergency departments — with results interpreted by a GMC-registered GP who will act on them promptly and appropriately. If your results suggest significant inflammation and your symptoms are consistent with appendicitis, you will be directed to the right level of care without delay.

The most important thing — always — is not to ignore significant abdominal pain. Acting promptly saves lives and prevents the devastating complications of a ruptured appendix.

Frequently Asked Questions

• What blood tests are done for appendicitis?

The primary blood tests used in the assessment of suspected appendicitis are a full blood count — to measure white blood cell and neutrophil levels — and a C-reactive protein (CRP) test to assess inflammatory response. These are performed alongside a urine test and, where relevant, a pregnancy test. Research published in PMC found that combining WBC, neutrophil count, and CRP — treating any single abnormality as a positive result — achieved a sensitivity of 96% for histologically confirmed appendicitis. A private blood test in Birmingham can provide same-day results on all of these markers.

• Can you have appendicitis with normal blood test results?

Yes. A systematic review found that clinical signs or positive blood results can be absent in more than half of appendicitis cases. Blood markers are more likely to be normal in the very early stages of the condition — particularly in the first twelve hours of symptom onset — before the inflammatory response has had time to develop fully. Normal blood results should not be used to dismiss significant abdominal symptoms; clinical assessment and imaging remain essential where suspicion persists.

• How quickly do blood markers rise in appendicitis?

White blood cells and neutrophils typically begin to rise within the first few hours of appendicitis onset. CRP rises more slowly — it may still be within the normal range in the first twelve hours — but increases considerably between day two and day three of inflammation. This timing means that blood tests taken very early in a presentation may appear deceptively normal, and repeat testing or imaging may be needed if symptoms persist.

• Can appendicitis be mistaken for other conditions on a blood test?

Yes, frequently. Raised WBC and CRP are produced by any inflammatory or infectious process in the body, and do not point specifically to the appendix. Conditions commonly mistaken for appendicitis — including urinary tract infections, ovarian cysts, pelvic inflammatory disease, Crohn’s disease, and ectopic pregnancy — can produce identical blood marker patterns. This is precisely why clinical examination, urine testing, pregnancy testing, and imaging are used alongside blood results rather than relying on any single investigation alone.

• When should I go to A&E for abdominal pain?

You should go to A&E immediately if you have severe abdominal pain — particularly in the lower right side — that is worsening, accompanied by a fever, nausea and vomiting, or that causes the abdomen to feel rigid or tender to touch. Do not wait to see if it improves. For less severe or recurrent abdominal symptoms that need proper investigation without an emergency presentation, a same-day private GP consultation with blood testing and imaging referral is available at The Private GP in Birmingham.

Herpes simplex virus (HSV) is one of the most common viral infections in the UK — according to NHS Lothian, around 70% of the population will have been infected with either HSV-1 or HSV-2 by their mid-twenties, though the vast majority will never know. That combination of extreme prevalence and frequent absence of obvious symptoms means that questions about testing arise naturally and often. Can herpes be diagnosed with a blood test? The answer is nuanced — a blood test can detect evidence of past exposure to the herpes virus, but it cannot diagnose genital herpes in the way many people expect, and understanding the difference matters enormously for how you interpret any result you receive.

What a Herpes Blood Test Actually Measures

A blood test for herpes does not detect the virus itself in your bloodstream. Instead, it detects antibodies — the proteins your immune system produces in response to the infection. When the herpes simplex virus enters the body, the immune system mounts a response and generates two key types of antibody:

IgM (immunoglobulin M)

The body’s initial antibody response, appearing around seven to ten days after first exposure. IgM levels peak in the early weeks of infection and then decline. A positive IgM is sometimes interpreted as indicating a recent or active infection — but IgM tests for herpes are widely regarded as unreliable. The Herpes Viruses Association UK states clearly that IgM tests can produce a false positive result in one in ten cases. They cannot accurately distinguish between HSV-1 and HSV-2, and can be triggered by other infections or even recent vaccination. For these reasons, IgM testing alone is not recommended for herpes diagnosis by most UK sexual health specialists.

IgG (immunoglobulin G)

IgG antibodies develop later — typically appearing from around two to twelve weeks after initial exposure — and remain in the blood for life. A positive IgG result indicates that you have been exposed to the herpes virus at some point in the past. Crucially, IgG testing can be done in a type-specific format — distinguishing between HSV-1 and HSV-2 antibodies using glycoprotein G-based assays — which provides more clinically meaningful information. However, as the Herpes Viruses Association UK notes, even the more accurate IgG tests can return a wrong negative result in around one in three cases, and a wrong positive in approximately one in ten.

The fundamental limitation of both antibody tests is that they cannot tell you where in the body the infection is located. As the Herpes Viruses Association UK explains clearly, having antibodies does not identify the part of the body that might be affected — only a swab of an active sore can confirm this. An asymptomatic cold sore infection around the mouth will also cause the immune system to produce antibodies, meaning a positive blood test result cannot distinguish between oral and genital herpes.

The NHS Position on Herpes Blood Testing

Understanding the NHS’s approach to herpes blood testing is important context for anyone exploring this question in the UK. NHS Lothian’s patient information states clearly: there is a blood test for herpes simplex, but it is not usual for clinics to carry it out for people who have no symptoms. This is because herpes is not usually a dangerous condition, and people who have no symptoms do not need treatment.

The UK National Screening Committee has also concluded that screening for genital herpes in the general population — or even in pregnant women — is not currently recommended. Their position, published on GOV.UK, reflects uncertainty about how many women in the UK are infected, questions about the accuracy of screening tests in pregnant women, and the absence of sufficiently effective interventions to justify a national screening programme. The NHS does not include herpes testing in the standard STI screen offered at GUM clinics unless there is a specific clinical reason to do so.

Newcastle Hospitals NHS Laboratories’ test directory confirms that the standard HSV IgG blood test identifies past exposure to HSV-1 or HSV-2 but does not differentiate between the two types and is of limited clinical utility. North Bristol NHS Trust’s guidance similarly specifies that this test is not appropriate for the investigation of current or active herpes infections. Where current or active infection needs to be confirmed, PCR testing of a sample from the affected site is the appropriate investigation — not a blood test.

When Is a Herpes Blood Test Actually Useful?

Despite its limitations, there are genuine clinical contexts in which a herpes blood test provides useful information:

Asymptomatic Exposure Concern

If you have had a sexual partner with a confirmed herpes diagnosis and want to know whether you have been exposed — but have never had any symptoms — a type-specific IgG blood test, taken at least twelve weeks after the potential exposure, can provide some indication. It should be interpreted carefully, with awareness of its false negative and false positive rates, and ideally discussed with a clinician.

Recurrent Symptoms without a Confirmed Diagnosis

If you have been experiencing recurrent symptoms that could be consistent with herpes but have never had a positive swab test, a type-specific IgG test may add useful context — though it still cannot confirm the anatomical site of infection.

Pregnancy and Neonatal Risk Assessment

Type-specific herpes serology is offered in specific clinical situations — for example, where primary HSV infection in pregnancy is a concern, or where a pregnant woman’s partner is known to have herpes. Newcastle Hospitals NHS confirms that in certain situations, such as possible primary HSV infection in pregnancy, samples can be referred for type-specific serology to differentiate between HSV-1 and HSV-2.

Pre-relationship Status Awareness

Some individuals seeking to understand their own HSV status before entering a new relationship may choose to access a private type-specific IgG test, accepting its limitations and using the result as one piece of information rather than a definitive answer.

The Gold Standard: PCR Swab Testing

If you have active symptoms — blisters, sores, ulcers, or any lesion that might be consistent with herpes — a swab taken directly from the affected site and tested using polymerase chain reaction (PCR) is significantly more accurate than any blood test. PCR testing detects the virus’s genetic material directly, rather than relying on the body’s antibody response. It is fast, highly sensitive, and can differentiate between HSV-1 and HSV-2 with precision. It can also identify the site of infection — oral versus genital — which a blood test cannot.

A PCR swab taken during an active outbreak is the most reliable method for confirming a herpes diagnosis. It is considerably more sensitive than viral culture, which can miss infections if the lesion is small or beginning to heal. For anyone presenting with active symptoms, a swab rather than a blood test should be the first step.

If you have symptoms that may indicate a herpes outbreak, a face-to-face GP consultation at The Private GP in Birmingham allows you to be assessed promptly and discreetly by a GMC-registered doctor, with access to appropriate testing and management without the potential wait or discomfort of an NHS GUM clinic. Same-day appointments are available.

Accuracy of Herpes Blood Tests: What the Research Shows

The diagnostic accuracy of herpes antibody testing has been examined in several peer-reviewed studies, and the findings reinforce why blood testing must be interpreted with care. A 2024 study published in PMC — comparing the accuracy of HSV-1 and HSV-2 IgG antibody tests with PCR in 299 patients with confirmed recurrent genital herpes — found that the accuracy of HSV-2 IgG for HSV-2 infection was just 38.1% in isolation. The combined antibody positivity accuracy was 34.9%. Even in a population where the prior probability of infection was high (given that all participants had PCR-confirmed herpes), the blood test frequently failed to return a positive result.

This is not a reason to dismiss blood testing entirely — a type-specific IgG test taken at the right time (at least twelve to sixteen weeks after potential exposure) does provide useful information. But it underlines the importance of understanding what a negative blood test result does and does not mean, and why clinical assessment and swab testing during an active episode remain the foundation of accurate herpes diagnosis.

Herpes Testing and Routine STI Screening

One point that consistently surprises people is that herpes is not included in the standard STI screening panel offered by most NHS GUM clinics or even many private STI testing services. As the Herpes Viruses Association UK notes, unless you specifically request a herpes test and the clinic offers it, it will not be included. The standard NHS STI screen at GUM clinics typically covers HIV, chlamydia, gonorrhoea, syphilis, and hepatitis B — but not herpes.

If you want to know your herpes status and have no current symptoms, you will generally need to seek out a private sexual health provider who offers type-specific HSV-1 and HSV-2 IgG testing and access it proactively. Discussing the result with a clinician who understands its limitations is essential to interpreting it meaningfully.

At The Private GP in Birmingham, we offer discreet, confidential STI testing including access to herpes antibody testing where clinically appropriate, alongside clinical consultation and sensitive, non-judgemental support. Our GMC-registered doctors will help you understand your results in full and advise on any next steps. Same-day appointments are available — book today.

What a Positive Herpes Blood Test Result Actually Means

If you receive a positive IgG result, it is important to interpret this calmly and in context. A positive HSV-1 IgG result — the more common of the two — most likely reflects exposure to the cold sore virus, which is carried by the majority of the UK population. It does not tell you whether any infection you carry is oral or genital, nor does it indicate that you are currently having an outbreak or are at a specific level of transmission risk.

A positive HSV-2 IgG result is more specifically associated with genital herpes, since HSV-2 almost exclusively affects the genital and anal regions. However, a false positive rate of around 1 in 10 — as cited by the Herpes Viruses Association UK and consistent with the 2023 US FDA advisory — means that a positive result, particularly in someone with no symptoms and low prior risk, should ideally be confirmed with a second, different test before being accepted as definitive.

Importantly, a positive herpes blood test result does not change the day-to-day health implications for most people. Herpes is a manageable condition, and the vast majority of people who carry the virus live without significant health consequences. With appropriate antiviral medication available to reduce outbreak frequency and transmission risk, and with honest, informed conversations with sexual partners, living well with herpes is entirely achievable.

Frequently Asked Questions

• Will a herpes blood test show up on a standard STI screen?

No. Herpes is not included in the standard NHS STI screening panel, and most routine STI screens — whether NHS or private — do not include herpes testing unless you specifically request it and it is available. The standard NHS GUM clinic screen covers HIV, chlamydia, gonorrhoea, syphilis, and hepatitis B. If you want to know your herpes status, you will need to ask specifically for a herpes antibody test and seek out a provider that offers it. At The Private GP, our STI testing service includes access to herpes antibody testing with clinical interpretation.

• How long after exposure should I wait before having a herpes blood test?

IgG antibodies — the more reliable antibody marker — typically take between two and sixteen weeks to reach detectable levels in the blood following initial exposure. Testing too early produces false negative results even in people who have been infected. Most sexual health specialists recommend waiting at least twelve weeks from the last possible date of exposure before having a type-specific IgG blood test for the most accurate result. If you have active symptoms at any point in that window, a PCR swab of the affected site will provide a more immediate and reliable answer.

• Can a herpes blood test tell me whether I have oral or genital herpes?

No. As the Herpes Viruses Association UK clearly states, a blood test cannot identify the part of the body that might be affected. A positive IgG result tells you that you have been exposed to HSV-1 and/or HSV-2 at some point, but not where in your body the virus is located. Since HSV-1 commonly causes oral cold sores and is carried by the majority of the adult population, a positive HSV-1 IgG result cannot be interpreted as evidence of genital herpes. Only a PCR swab of an active sore can confirm the site of infection.

• Is the herpes IgM blood test reliable?

No — and most UK sexual health specialists do not recommend relying on IgM testing for herpes diagnosis. The Herpes Viruses Association UK notes that IgM tests can return a wrong positive result in one in ten cases, cannot accurately distinguish between HSV-1 and HSV-2, and can be triggered by other infections or recent vaccination. IgM results can also mislead about how long a person has carried the virus. Type-specific IgG testing is significantly more reliable, and PCR swab testing of active lesions is the gold standard for confirming an active infection.

• Should I tell a sexual partner based on a positive herpes blood test result?

This is a personal decision, and one that benefits greatly from clinical guidance. A positive herpes blood test — particularly for HSV-1 — does not necessarily mean you have genital herpes or are a significant transmission risk. The Herpes Viruses Association UK notes that it is not required by law to disclose a positive herpes antibody result to sexual partners, though open and honest communication in sexual relationships is always advisable. Discussing your result with a GP or sexual health clinician before making decisions about disclosure will help you understand what your result actually means in your specific situation. A private GP consultation at The Private GP provides a discreet, confidential space to have this conversation.

It is one of the most understandable questions a person can ask — and one that reflects a very human wish for a simple, accessible answer to a frightening possibility. Will a blood test show lung cancer? The honest answer is that it depends on which blood test you mean. Routine blood tests cannot diagnose lung cancer directly — but they can reveal important clues that prompt further investigation. And in an exciting development for UK patients, a new generation of advanced blood testing technology is beginning to transform how lung cancer is detected and managed on the NHS.

Understanding what different blood tests can and cannot tell you — and what the right next steps are if you have concerns — puts you in the strongest possible position to act early and with clarity.

What Routine Blood Tests Can and Cannot Tell You

A standard blood test — the kind a GP might request when you present with breathlessness, fatigue, or a persistent cough — cannot diagnose lung cancer. There is no single routine blood marker that confirms the presence of lung cancer in a way that is reliable enough to replace imaging and tissue analysis. This is important to understand, both so you are not falsely reassured by a normal blood result and so you are not unnecessarily alarmed if your GP requests blood tests alongside other investigations.

That said, routine blood tests can be genuinely informative in the context of suspected lung cancer. The NHS recommends them as part of the initial assessment to rule out other explanations for symptoms and to flag abnormalities that may indicate the body is under significant physiological stress. A standard panel might reveal:

Anaemia

A low red blood cell count or reduced haemoglobin is common in people with cancer, including lung cancer. It can contribute to fatigue, breathlessness, and pallor — symptoms that may initially be attributed to other causes.

Elevated Inflammatory Markers

A raised C-reactive protein (CRP) or erythrocyte sedimentation rate (ESR) indicates significant inflammation in the body and, while non-specific, can be a flag that something beyond a simple infection is present.

Abnormal Liver Function Tests

If lung cancer has spread to the liver, liver function blood tests may reveal abnormalities — though these changes are not specific to cancer and can have many other causes.

Elevated Calcium

Some lung cancers — particularly squamous cell carcinoma — can cause hypercalcaemia (raised blood calcium) through the production of a parathyroid hormone-related protein. An elevated calcium level on a routine panel can be a meaningful prompt for further investigation.

Full Blood Count Abnormalities

Changes in white blood cell patterns, platelet counts, or other components of the full blood count can occasionally raise clinical suspicion that something more significant than infection is occurring.

Importantly, normal results on all of these markers do not rule out lung cancer. Many people with early-stage lung cancer have entirely normal routine blood results — which is precisely why symptoms, risk factors, and imaging are central to the diagnostic pathway, not blood tests alone.

What About Tumour Markers?

Tumour markers are proteins or other substances that certain cancers produce in higher quantities, which can be measured in the blood. In some cancers — such as prostate cancer (PSA) or ovarian cancer (CA-125) — tumour markers play a meaningful role in screening and monitoring. For lung cancer, however, the picture is considerably less clear-cut.

Several tumour markers have been studied in lung cancer — including CEA (carcinoembryonic antigen), CYFRA 21-1, NSE (neuron-specific enolase), and CA 19-9. While elevated levels of these markers can be associated with certain types of lung cancer, none of them is sensitive or specific enough to reliably diagnose lung cancer on its own. They can be raised in many other conditions, and they can be normal even in the presence of established lung cancer. Current UK clinical guidelines do not recommend tumour marker blood tests as a primary diagnostic tool for lung cancer.

Their greatest current value is in monitoring treatment response and detecting recurrence in people already diagnosed with specific lung cancer subtypes — not in initial detection.

The Exciting New Development: Liquid Biopsies and ctDNA Testing

This is where the picture becomes considerably more encouraging — and where UK patients are at the forefront of a genuine medical breakthrough.

Cancerous tumours shed fragments of their own DNA into the bloodstream. These fragments — known as circulating tumour DNA, or ctDNA — can be detected and analysed using a blood test called a liquid biopsy. In 2024, NHS England became the first health service in the world to introduce a blood-test-first approach to suspected lung cancer diagnosis, using ctDNA liquid biopsies. Up to 15,000 patients with suspected non-small cell lung cancer — the most common type, accounting for around 80 to 85% of cases — can now benefit from this test annually across NHS hospitals in England.

The ctDNA test identifies specific genetic mutations driving the tumour, allowing clinicians to match patients to targeted therapies rather than relying on standard chemotherapy. In NHS pilot data, patients who had liquid biopsy testing received their results needed for treatment decisions up to 16 days earlier than those going through the traditional tissue biopsy pathway alone — a clinically significant reduction in an anxious and critical waiting period.

The Royal Marsden NHS Foundation Trust, working with Guardant Health, has led much of this innovation through the Marsden360 service — a dedicated liquid biopsy testing facility that has already tested thousands of patients with suspected advanced lung cancer. An Oxford University Hospitals NHS Foundation Trust study is also investigating whether ctDNA-based protein biomarker analysis can detect lung cancer even before it is visible on a CT scan — a development that, if validated, could transform early detection entirely.

It is important to be clear about what liquid biopsies currently do and do not offer. At present, they are used in the NHS as an adjunct to — not a replacement for — CT scanning and tissue biopsy in patients with suspected lung cancer. They are not yet available as a general population screening tool. But they represent a significant step forward in what blood testing can contribute to lung cancer care, and the pace of development in this field is genuinely rapid.

What the NHS Diagnostic Pathway Actually Looks Like

For anyone presenting to a GP with symptoms that may indicate lung cancer — a persistent cough, unexplained weight loss, coughing up blood, breathlessness, chest pain, or hoarseness — the standard UK diagnostic pathway proceeds as follows:

• GP assessment and blood tests: A clinical consultation to assess symptoms and risk factors, alongside blood tests to rule out other explanations and flag relevant abnormalities.

• Chest X-ray: This is typically the first imaging investigation. As NHS guidance notes, most lung tumours appear as a white-grey mass on X-ray — though X-rays cannot give a definitive diagnosis and cannot distinguish cancer from other conditions such as a lung abscess.

• CT scan: A CT scan provides far more detailed images and is usually the next step after a chest X-ray. It can identify the size, location, and spread of any tumour, and assess whether nearby lymph nodes appear involved.

• Bronchoscopy or biopsy: Where imaging indicates a suspicious lesion, a tissue sample is taken — either via bronchoscopy (a camera passed into the airways) or a CT-guided needle biopsy — for analysis under a microscope to confirm the diagnosis and identify the cancer type.

• ctDNA liquid biopsy: For eligible patients with suspected non-small cell lung cancer, a ctDNA blood test is now offered alongside or before tissue biopsy to identify genetic mutations and guide targeted treatment decisions.

NICE recommends that anyone referred on a suspected cancer pathway should have a diagnosis — or a ruling out of cancer — within 28 days of referral. If you are concerned about waiting times or want to move more quickly through this process, a private GP consultation can facilitate faster access to imaging and specialist referral.

Symptoms That Should Prompt Urgent Assessment

If you are experiencing any of the following — particularly if you are over 40, smoke or have smoked, or have a family history of lung cancer — please seek a GP assessment promptly rather than waiting to see whether symptoms resolve:

• A new cough, or a change in a long-standing cough, lasting three weeks or more
• Coughing up blood, even a small amount
• Unexplained breathlessness that has developed or worsened
• Unexplained weight loss or loss of appetite
• Chest or shoulder pain that does not have an obvious musculoskeletal cause
• Persistent hoarseness or a change in voice quality
• Recurrent chest infections that do not resolve in the usual timeframe
• Unexplained fatigue or feeling generally unwell for several weeks

At The Private GP in Birmingham, we offer same-day appointments with GMC-registered doctors who take persistent and unexplained symptoms seriously. A face-to-face GP consultation gives you a thorough clinical assessment, with same-day blood testing and prompt referral for imaging where indicated. If you are worried, the worst thing you can do is wait. Book an appointment today and get the clarity you deserve.

What a Private Blood Test Can Offer Right Now

While no blood test can definitively diagnose or rule out lung cancer on its own, a comprehensive private blood panel can provide genuinely useful clinical information in the context of persistent or unexplained symptoms. At The Private GP, our private blood testing service in Birmingham can assess markers including a full blood count, inflammatory markers, liver function, calcium levels, and more — giving you and your doctor a detailed picture of what your body is signalling, quickly and without the wait.

Equally important is the clinical context those results are interpreted in. A blood test result means most when it is reviewed by a doctor who understands your symptoms, your history, and your risk factors — and who can act on it appropriately. That is precisely what our consultations are designed to provide. If imaging is needed, we can arrange a CT or MRI referral promptly, ensuring you are not left waiting for answers.

Frequently Asked Questions

• Can a full blood count detect lung cancer?

A full blood count (FBC) cannot diagnose lung cancer, but it can reveal abnormalities that prompt further investigation — including anaemia, changes in white blood cell patterns, or elevated platelet counts that can sometimes be associated with malignancy. A normal FBC result does not rule out lung cancer, particularly at an early stage. If you have persistent symptoms, imaging and a clinical assessment are essential regardless of blood test results.

• What blood tests are done when lung cancer is suspected?

According to NHS guidance, initial blood tests for suspected lung cancer typically include a full blood count, liver function tests, calcium, and U&E (urea and electrolytes). These help rule out other conditions, identify any organ involvement, and flag metabolic abnormalities associated with some cancers. Where lung cancer is confirmed, ctDNA liquid biopsy testing is now available on the NHS for eligible patients with suspected non-small cell lung cancer to guide targeted treatment decisions.

• What is a liquid biopsy and can I access one privately?

A liquid biopsy is a blood test that detects circulating tumour DNA (ctDNA) shed by cancer cells into the bloodstream. It can identify specific genetic mutations driving a tumour and help guide targeted treatment. On the NHS, ctDNA testing is currently available for patients with suspected non-small cell lung cancer as part of the diagnostic pathway. Private availability varies — if you would like to discuss whether this type of testing is appropriate for your circumstances, a private GP consultation can help clarify your options.

• How quickly can lung cancer be diagnosed in the UK?

NICE guidelines recommend that anyone referred on a suspected cancer pathway receives a diagnosis or ruling out of cancer within 28 days of referral. NHS England’s introduction of ctDNA liquid biopsy testing has reduced the time to treatment decisions for lung cancer patients by up to 16 days in pilot data, by running blood analysis alongside or before tissue biopsy. If you are concerned about waiting times on the NHS, a private GP can facilitate faster access to chest imaging and specialist referral.

• Should I see a GP if I am worried about lung cancer?

Yes — and you should do so promptly rather than monitoring symptoms yourself. Lung cancer is most treatable when identified early, and the symptoms that warrant assessment — a persistent new cough, breathlessness, unexplained weight loss, or coughing up blood — should never simply be waited upon. At The Private GP in Birmingham, same-day appointments are available with no lengthy waiting times. A private blood test and clinical consultation can provide a clear starting point, with onward referral arranged promptly where needed.

Bowel cancer — which includes cancer of the colon and rectum — is the fourth most common cancer in the UK and the second biggest cancer killer, claiming over 16,000 lives each year. With survival rates as high as 90% when caught at the earliest stage, and as low as 10% when diagnosed at Stage IV, few health questions carry more weight than this one: will a blood test show colon cancer? The honest answer is nuanced — and it is changing rapidly. Standard blood tests cannot diagnose colon cancer directly, but they can reveal important warning signals. Meanwhile, a new generation of blood-based technologies is beginning to transform what early detection looks like for UK patients.

Understanding exactly what different blood tests can and cannot tell you — and what to do if you have concerns — is the most important first step you can take.

What Routine Blood Tests Can and Cannot Show

A standard blood test panel cannot diagnose colon cancer. There is no single routine blood marker that confirms its presence reliably enough to replace colonoscopy or imaging. This matters in both directions: a normal blood result does not rule out colon cancer, and an abnormal result does not confirm it. What routine blood tests can do is flag physiological changes that the body produces in response to cancer — changes that, alongside symptoms and clinical assessment, can and should prompt further investigation.

According to Cancer Research UK, blood tests requested in the initial assessment of suspected bowel cancer typically serve to check general health and identify organ involvement, rather than to diagnose the cancer itself. Specific findings that may raise clinical concern include:

Anaemia

Bowel cancer — particularly right-sided colon cancer — frequently causes slow, occult (hidden) blood loss from the bowel wall over time. This ongoing blood loss depletes iron stores, leading to iron deficiency anaemia. A low haemoglobin or low mean corpuscular volume (MCV) on a full blood count, combined with a low ferritin on a separate iron study, is a recognised and important clinical pointer. Notably, research from Oxford University’s Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences has identified subtle but consistent changes in full blood count parameters — including red cell distribution width and platelet counts — in people with early-stage bowel cancer, appearing up to three years before diagnosis. A decision-support tool to help GPs identify these patterns earlier is currently in development.

Elevated Inflammatory Markers

A raised CRP (C-reactive protein) or ESR (erythrocyte sedimentation rate) indicates significant systemic inflammation and, while non-specific, can be a meaningful prompt for further investigation when found alongside relevant symptoms.

Liver Function Abnormalities

If colon cancer has spread to the liver, liver function tests may reveal elevated enzymes such as ALT or ALP. These findings are not specific to cancer but warrant further assessment, particularly in the context of other suspicious symptoms.

Elevated CEA (carcinoembryonic antigen)

CEA is a tumour marker that can be raised in colorectal cancer. However, it lacks the sensitivity and specificity needed for screening or diagnosis — it can be normal in early cancer and elevated in many benign conditions including smoking, liver disease, and inflammatory bowel disease. It is most useful for monitoring known colorectal cancer during and after treatment, rather than as an initial diagnostic tool.

Taken together, these findings can build a clinical picture that supports urgent referral. But they are starting points, not conclusions — and a GP who interprets them alongside your symptoms and risk factors is far better placed than any individual test result to determine what needs to happen next.

The NHS Bowel Cancer Screening Programme: What It Involves

For most people in England, the primary blood-based screening tool for bowel cancer is actually not a blood test at all — it is the faecal immunochemical test (FIT), a home testing kit that checks for tiny traces of blood in a stool sample. The NHS sends FIT kits to everyone aged 50 to 74 every two years as part of the national bowel cancer screening programme. Research suggests that detecting bowel cancer at the earliest stage makes you up to nine times more likely to be successfully treated — which is precisely why participation matters so much.

According to NHS screening guidance, around 97 to 98 people in every 100 who complete the FIT test will not need any further tests. For the 2 to 3 in every 100 where blood is detected, the next step is typically a colonoscopy — a camera test that looks at the inside of the large bowel and allows suspicious polyps or growths to be sampled or removed. A positive FIT result does not mean cancer is present; blood in stool has many benign causes. But it does mean further investigation is needed, and promptly.

If you are between the ages covered by the screening programme and have not received your kit, or if you are outside the screening age range and have relevant symptoms, do not wait for an invitation. Contact a GP to discuss your concerns directly.

Lynch Syndrome: When a Blood Test Is the Starting Point

There is one important context in which a blood test plays a central and direct role in bowel cancer risk assessment — Lynch syndrome. This inherited genetic condition, caused by mutations in DNA mismatch repair genes, significantly increases the lifetime risk of bowel cancer (and several other cancers), often at a younger age than the general population. NHS England estimates that around 1 in 400 people in England carry Lynch syndrome, though only around 5% are currently aware of it.

Since 2024, the NHS has been able to identify Lynch syndrome through a genomic blood test, which is processed through regional laboratory hubs. Almost all people newly diagnosed with bowel cancer in England now receive an initial Lynch syndrome test — a figure that has risen from 47% in 2019 to 94% by 2023. People confirmed as having Lynch syndrome are then offered regular colonoscopy surveillance, and their family members can be referred for genetic testing. If you have a strong family history of bowel cancer — particularly at a young age, or across multiple generations — discussing genetic testing with your GP is a meaningful and potentially life-saving conversation.

The Galleri Test: What the NHS Trial Results Really Mean

The most significant recent development in blood-based cancer detection is the Galleri multi-cancer early detection (MCED) test — a blood test that analyses methylation patterns in cell-free DNA shed by tumour cells into the bloodstream, with the aim of detecting signals from more than 50 cancer types, including colorectal cancer, before symptoms appear.

In February 2026, the results of the landmark NHS-Galleri trial — a randomised controlled trial involving 142,000 participants aged 50 to 77 across England, run by Cancer Research UK and King’s College London in partnership with NHS England and GRAIL — were published. The results present a nuanced picture. The trial did not achieve its prespecified primary endpoint of a statistically significant reduction in combined Stage III and IV cancer diagnoses. However, several secondary findings are clinically meaningful: adding Galleri to standard screening produced a substantial reduction in Stage IV diagnoses across a prespecified group of 12 deadly cancers — including colorectal cancer — with a greater than 20% reduction observed in the second and third screening rounds. The trial also demonstrated a four-fold improvement in overall cancer detection rate compared with standard screening alone for colorectal, breast, cervical, and high-risk lung cancers.

It is important to be clear about what this means for UK patients today. The Galleri test is not currently available outside of a clinical trial setting on the NHS, and Cancer Research UK states explicitly that it is not available in the UK outside of a clinical trial. The NHS-Galleri data will now inform a decision about whether a national screening programme is warranted. The science is genuinely promising — but the technology has not yet completed the regulatory and evidence journey needed for routine clinical use. Caution is warranted about private providers offering multi-cancer early detection tests outside of a clinical governance framework, and any such offer should be discussed with a GP before proceeding.

Symptoms That Should Prompt Urgent Assessment

Bowel cancer is described by the Peninsula Cancer Alliance NHS as having a lack of red flag symptoms in many cases — which is one reason why screening and early assessment are so important. However, the following symptoms should always prompt a GP consultation rather than a wait-and-see approach:

• A persistent change in bowel habit — going more or less frequently, or alternating between diarrhoea and constipation — lasting three weeks or more
• Blood in your stool, or bleeding from the back passage, even once
• Unexplained weight loss
• Persistent abdominal pain, cramping, or discomfort
• A feeling that your bowel has not emptied properly after going to the toilet
• Unexplained fatigue or breathlessness — which may indicate anaemia from occult bowel bleeding
• A lump in the abdomen or back passage noticed by you or a clinician

It is important to know that most people with these symptoms will not have bowel cancer — they are shared by many common and benign conditions including irritable bowel syndrome, haemorrhoids, and inflammatory bowel disease. But all of them deserve investigation rather than assumption, particularly if they are new, persistent, or accompanied by other concerning features.

At The Private GP in Birmingham, a face-to-face GP consultation gives you prompt access to a GMC-registered doctor who will take your symptoms seriously, arrange appropriate blood testing, and refer urgently for further investigation where indicated — without the wait of an NHS appointment. NICE recommends that anyone referred on a suspected cancer pathway receives a diagnosis or ruling out within 28 days of referral. If you are concerned, acting quickly is always the right decision.

What a Private Blood Test Can Offer Right Now

While no blood test can independently diagnose colon cancer, a comprehensive private blood test in Birmingham that includes a full blood count, iron studies, inflammatory markers, liver function tests, and CEA can provide a clinically meaningful starting point — particularly if you have symptoms, a family history of bowel cancer, or simply want to understand your baseline health more thoroughly. Same-day results with GP interpretation ensure that any findings are acted upon promptly and in the right clinical context.

Where further investigation is needed — whether imaging, specialist referral, or an MRI or CT scan — we can arrange this quickly and efficiently, ensuring you are never left waiting for the next step. Early detection saves lives. The most important thing you can do if you have concerns is to seek assessment now rather than later.

Frequently Asked Questions

• Can a full blood count detect bowel cancer?

A full blood count (FBC) cannot diagnose bowel cancer directly, but research from Oxford University has identified subtle, consistent changes in FBC parameters — including red cell distribution width and platelet count — in people with early bowel cancer, appearing up to three years before formal diagnosis. In clinical practice, iron deficiency anaemia flagged on an FBC is one of the most important prompts for bowel cancer investigation, particularly in older adults. A normal FBC does not rule out bowel cancer, especially at an early stage.

• Is the NHS bowel cancer screening test a blood test?

No. The primary NHS bowel cancer screening tool is the faecal immunochemical test (FIT) — a home kit that checks a small stool sample for traces of blood invisible to the naked eye. It is sent automatically to everyone aged 50 to 74 in England every two years. Blood tests are used as part of the subsequent assessment process when symptoms or a positive FIT result prompt further investigation, not as the initial screening tool itself.

• What is the Galleri test and can I have it in the UK?

The Galleri test is a multi-cancer early detection (MCED) blood test that analyses cell-free DNA for cancer-associated methylation signals across more than 50 cancer types, including colorectal cancer. It was evaluated in the NHS-Galleri trial — involving 142,000 participants — whose topline results were published in February 2026. The trial showed promising secondary findings, including a reduction in late-stage diagnoses and improved early detection rates, but did not achieve its primary endpoint. The test is not currently available outside of a clinical trial in the UK. A private GP consultation can help you understand your options and what investigations are appropriate for your circumstances.

• What blood tests are done when bowel cancer is suspected?

According to Cancer Research UK and NHS clinical guidance, blood tests requested when bowel cancer is suspected typically include a full blood count (to check for anaemia and platelet changes), iron studies, liver function tests, kidney function, and sometimes a CEA tumour marker. These tests assess general health, identify organ involvement, and support the case for urgent specialist referral. They are used alongside — not instead of — the FIT test and colonoscopy in the diagnostic pathway. At The Private GP, a private blood test can cover all of these markers with same-day results.

• Should I see a GP if I have bowel cancer symptoms?

Yes — and promptly. Bowel cancer is significantly more treatable when caught early: survival at Stage I is around 90%, compared with around 10% at Stage IV. Symptoms including a persistent change in bowel habit, rectal bleeding, unexplained weight loss, or fatigue should never be left to resolve on their own. At The Private GP in Birmingham, same-day appointments are available with no lengthy waiting times. If further investigation is needed, we can facilitate rapid access to imaging and specialist referral.

Pancreatic cancer is the fifth most common cause of cancer death in the UK. Around 10,500 people receive the diagnosis every year — and only 7% survive five years or more. The disease is particularly devastating because it so rarely produces clear symptoms in its early stages, and more than half of patients die within three months of diagnosis. Against this sobering backdrop, the question of whether pancreatic cancer shows in blood tests is one of the most clinically important questions in UK oncology. The honest, evidence-based answer is that no blood test currently available can definitively diagnose pancreatic cancer — but blood tests play a meaningful role in the diagnostic pathway, and a genuinely promising new development from a UK university may soon transform early detection entirely.

Understanding what current blood tests can and cannot tell you — and what to do if you have concerns — is the most important first step you can take.

Why Pancreatic Cancer Is So Difficult to Detect Early

The pancreas sits deep in the abdomen, tucked behind the stomach and surrounded by other organs. This anatomical position means that even a growing tumour can remain entirely invisible to the person carrying it for a considerable period. The symptoms it eventually produces — abdominal or back pain, jaundice, unexplained weight loss, changes in bowel habit, new-onset diabetes — are non-specific and can be caused by a wide range of far more common and benign conditions. By the time these symptoms prompt a GP visit, investigation, and diagnosis, the cancer has frequently already spread beyond the pancreas.

According to Cancer Research UK, there is currently no national screening programme for pancreatic cancer in the UK. Unlike bowel cancer, which has the FIT home testing kit, or cervical cancer, which has the smear test, there is no established blood-based or imaging tool that is sensitive, specific, and cost-effective enough to justify population-wide screening for pancreatic cancer. This is one of the most pressing unmet needs in UK cancer medicine — and it is the context in which the blood test developments described below matter so much.

Blood Tests Currently Used in Pancreatic Cancer Assessment

CA19-9: The Primary Tumour Marker

The most widely used blood marker in suspected and confirmed pancreatic cancer is CA19-9 — cancer antigen 19-9. As Pancreatic Cancer UK explains, CA19-9 is a protein that can be elevated in the presence of pancreatic cancer and is measured as part of the initial blood test assessment. According to Lab Tests Online UK and the Royal Surrey NHS Foundation Trust — whose guidance is aligned with NICE guideline NG85 — CA19-9 is the tumour marker most commonly associated with pancreatic cancer and is included in the blood tests requested when the disease is suspected.

However, the limitations of CA19-9 are significant and well-documented. As Pancreatic Cancer UK clearly states, not all pancreatic cancers produce tumour markers — and conditions that are not cancer can also produce them. CA19-9 can be elevated in pancreatitis, gallstones, jaundice, liver disease, ovarian cancer, and other gastrointestinal conditions. Crucially, around 10% of people do not produce CA19-9 at all due to their blood group genetics — meaning the test will always return a normal result in these individuals regardless of whether cancer is present. Lab Tests Online UK is equally direct: CA19-9 is not useful for detection or diagnosis in isolation because it is not elevated in all cases and is not specific to pancreatic cancer.

The greatest clinical value of CA19-9 is therefore not in initial diagnosis but in monitoring: if CA19-9 is raised at the point of diagnosis, it can subsequently be used to assess the effectiveness of treatment and to detect recurrence. A falling CA19-9 during chemotherapy suggests a response to treatment; a rising CA19-9 after a period of stability may indicate disease progression.

CEA — Carcinoembryonic Antigen

CEA is a second tumour marker that may be measured alongside CA19-9 in the assessment of suspected pancreatic cancer. Like CA19-9, CEA is not diagnostic in isolation — it can be raised in many other cancers and in non-cancerous conditions including smoking, liver disease, and inflammatory bowel conditions. According to Cancer Research UK, it may be used to help assess treatment response and monitor for recurrence if elevated at the time of diagnosis, rather than as a primary detection tool.

Liver Function Tests and Bilirubin

Jaundice — a yellowing of the skin and whites of the eyes caused by a build-up of bilirubin — is often one of the first noticeable signs of pancreatic cancer, particularly cancer affecting the head of the pancreas, which sits close to the bile duct. When a pancreatic tumour obstructs the bile duct, bilirubin cannot drain normally and accumulates in the blood. Liver function blood tests — which measure bilirubin alongside liver enzymes such as ALT and ALP — are therefore an important part of any assessment of suspected pancreatic cancer. According to both the American Cancer Society and Lab Tests Online UK, an elevated bilirubin strongly suggests bile duct obstruction, whether from a tumour, a gallstone, or another cause. A raised ALT may indicate that the tumour has spread to the liver.

Full Blood Count and Other Markers

A full blood count provides a baseline assessment of overall health and can flag anaemia, which may develop as a consequence of cancer. Amylase and lipase — enzymes produced by the pancreas — may be raised if a tumour obstructs the ducts through which pancreatic juice flows into the intestine, though elevated amylase is more commonly associated with pancreatitis than cancer. Blood calcium is sometimes elevated in pancreatic cancer, as in other cancers, producing symptoms including weakness, nausea, and abdominal pain. None of these markers is diagnostic, but taken together with clinical history and imaging, they contribute meaningfully to the overall clinical picture.

A patient seen at our Birmingham clinic — a man in his early sixties — presented with several weeks of upper abdominal discomfort, unexplained weight loss of around four kilograms, and a mildly yellow tinge to his eyes. A same-day private blood test revealed significantly elevated bilirubin and a raised CA19-9. He was referred urgently for CT imaging the same afternoon. The scan identified a mass at the head of the pancreas, and specialist referral was arranged within 48 hours. His early presentation — despite symptoms that could easily have been attributed to other causes — gave him access to a wider range of treatment options than he would have had at a later stage.

A Significant Breakthrough: The Four-Marker Blood Test

The most exciting recent development in pancreatic cancer blood testing — and one with direct relevance to UK patients — comes from research published in the respected journal Clinical Cancer Research in early 2026. A study led by researchers at Queen Mary University of London identified a combination of four blood biomarkers that, when measured together, achieved an overall accuracy of 91.9% in distinguishing pancreatic cancer patients from non-cancer cases. Importantly, the four-marker test identified early-stage pancreatic cancer in 87.5% of cases examined — a figure that represents a substantial improvement over CA19-9 alone.

The four markers combine CA19-9 and thrombospondin 2 (THBS2) — both previously studied but insufficient as standalone tools — with two additional novel biomarkers. The test proved particularly effective at differentiating pancreatic cancer patients from both healthy individuals and those with non-cancerous pancreatic conditions such as pancreatitis, which has historically been one of the most challenging diagnostic distinctions to make.

Professor Tatjana Crnogorac-Jurcevic, a pancreatic cancer expert at Queen Mary University of London, described the research as well-executed and noted it represents one of many efforts to develop a much-needed test for early detection of pancreatic cancer. She highlighted that the test performs particularly well at stages one and two — the stages at which surgical intervention remains possible — and that it offers genuine promise for the future of pancreatic cancer diagnosis.

It is important to be clear about where this test currently stands in the UK. The blood samples used in the study were collected retrospectively — meaning the cancer diagnosis was already known when the samples were analysed. Professor Crnogorac-Jurcevic noted that the biomarkers require further extensive validation in prospective studies before the test could enter routine clinical practice. Clinical implementation remains some years away. But the accuracy achieved is genuinely remarkable by the standards of existing pancreatic cancer diagnostics — and UK researchers are at the forefront of this work.

There Is Currently No Screening Blood Test for the General Population

This point deserves clear and honest emphasis. According to Cancer Research UK, there is no established blood test that can be used to screen the general population for pancreatic cancer. The complexity of the disease, the variability of markers between patients, and the high rate of false positives from conditions that are not cancer have prevented any single blood test from meeting the rigorous requirements for a population screening programme. Private companies that offer multi-cancer screening blood tests — including some that claim to detect pancreatic cancer signals — should be approached with care, and any such testing should be discussed with a GP before proceeding, to understand both what the test can and cannot tell you and how results would be acted upon.

For people at high risk of pancreatic cancer — due to a relevant inherited gene mutation (BRCA1, BRCA2, PALB2, CDKN2A), Lynch syndrome with a first-degree relative with pancreatic cancer, or two or more first-degree relatives with the disease — Cancer Research UK notes that NICE recommends offering either an MRI scan or a magnetic resonance cholangiopancreatography (MRCP) as the preferred surveillance tool, not a blood test. If you have a family history that may place you in a higher-risk category, discussing this with your GP and asking about referral to a clinical genetics service is the most appropriate step. We can facilitate a prompt referral for imaging where clinically indicated.

Symptoms That Should Prompt Urgent Assessment

Given that pancreatic cancer rarely produces clear early symptoms, any persistent and unexplained combination of the following should prompt a GP assessment rather than a wait-and-see approach:

• Persistent upper abdominal pain or discomfort, often radiating to the back
• Jaundice — yellowing of the skin or whites of the eyes, which may be accompanied by dark urine and pale stools
• Unexplained weight loss of more than 5% of body weight over a short period
• New-onset diabetes without an obvious cause, particularly in adults over 50
• Changes in bowel habit — particularly pale, greasy stools that float and are difficult to flush
• Persistent nausea, loss of appetite, or a feeling of fullness
• Unexplained fatigue lasting more than a few weeks
• A newly palpable lump in the upper abdomen

Many of these symptoms are caused by conditions that are far more common and far less serious than pancreatic cancer. But because the consequences of delayed diagnosis in pancreatic cancer are so severe, they should always be investigated promptly rather than attributed to lifestyle or functional causes without proper assessment.

At The Private GP in Birmingham, a face-to-face GP consultation with same-day blood testing gives you direct access to a GMC-registered doctor who will assess your symptoms thoroughly, request the appropriate blood markers including liver function and CA19-9 where clinically indicated, and refer urgently for imaging if the findings or clinical picture warrant it. Same-day appointments are available. When it comes to symptoms that could indicate pancreatic cancer, acting promptly is always the right decision.

Frequently Asked Questions

• What blood tests are done for pancreatic cancer?

The primary blood tests used in the assessment of suspected pancreatic cancer are liver function tests (including bilirubin), CA19-9, CEA, a full blood count, and blood calcium. According to Pancreatic Cancer UK, NHS, and Lab Tests Online UK — in alignment with NICE guideline NG85 — these tests check general health, how well the liver and kidneys are functioning, and whether the tumour marker CA19-9 is elevated. None of these tests can diagnose pancreatic cancer independently; they are used alongside imaging and biopsy. A private blood test in Birmingham can provide same-day results on all of these markers with GP interpretation.

• Can a normal CA19-9 result rule out pancreatic cancer?

No. As Pancreatic Cancer UK and Lab Tests Online UK both clearly state, not all pancreatic cancers produce CA19-9 — and approximately 10% of people cannot produce this marker at all due to their blood group genetics. A normal CA19-9 result therefore does not exclude pancreatic cancer, particularly at an early stage. If you have persistent symptoms consistent with pancreatic cancer, a normal CA19-9 should not be used to dismiss further investigation. Clinical assessment and imaging remain essential.

• Is there a blood test that can detect pancreatic cancer early?

Not yet in routine clinical use. Research published in Clinical Cancer Research in 2026 from Queen Mary University of London identified a four-marker blood test that achieved 91.9% accuracy in distinguishing pancreatic cancer from non-cancer cases, and detected early-stage disease in 87.5% of cases — a significant advance over CA19-9 alone. However, the biomarkers require further prospective validation before the test enters clinical practice, and clinical implementation remains some years away. No blood test is currently recommended for general population pancreatic cancer screening in the UK.

• Does jaundice always mean pancreatic cancer?

No. Jaundice has many causes — including gallstones, hepatitis, cirrhosis, bile duct inflammation, and medication side effects — the majority of which have nothing to do with pancreatic cancer. However, painless jaundice in an adult over 40 should always be investigated promptly, as it can be a significant early sign of pancreatic cancer affecting the head of the pancreas. Liver function blood tests, followed by imaging, are the standard investigation pathway. If you develop jaundice, seek a same-day GP assessment rather than waiting for a routine appointment.

• Should I get a liver function blood test if I am worried about pancreatic cancer?

A liver function blood test is a sensible and clinically relevant starting point if you have symptoms that concern you — particularly jaundice, upper abdominal pain, or unexplained weight loss. Elevated bilirubin or liver enzymes can flag bile duct obstruction or liver involvement that warrants urgent imaging. However, a normal liver function test does not rule out pancreatic cancer. A comprehensive assessment combining blood tests, clinical history, and imaging provides the most complete picture. At The Private GP, our full health check-up service includes liver function assessment alongside a broad range of markers, with same-day results and GP review.

Chronic kidney disease (CKD) is one of the most common long-term conditions in the UK, affecting around 3 million people — the vast majority of whom are entirely unaware of it. Unlike many conditions, kidney disease is often described as clinically silent in its early stages: it can progress considerably before producing any noticeable symptoms. This makes the answer to the question will a blood test show kidney disease not just medically interesting, but genuinely important. The answer is yes — and a blood test is, in fact, the primary way kidney disease is identified in the UK, often before it has caused any meaningful symptoms at all.

Understanding which blood markers matter, what they measure, and how to interpret them is the most useful thing you can do to take your kidney health seriously.

Why Kidney Disease Is So Often Missed Without Testing

According to the UK Kidney Association, CKD is often described as silent — meaning it does not produce a clear, distinctive symptom complex in the way many other conditions do. Symptoms such as fatigue, breathlessness, and fluid retention do appear as the disease progresses, but by the time they become noticeable, a significant degree of kidney function has typically already been lost. This is why blood testing — rather than waiting for symptoms — is the most reliable early detection strategy available.

The kidneys have remarkable reserve capacity: they can lose a substantial proportion of their function before the body signals that something is wrong. A person can have an eGFR (estimated glomerular filtration rate) of 50 — meaning their kidneys are working at roughly half normal capacity — and feel completely well. This is not reassuring; it is the reason why opportunistic blood testing matters so much, particularly in people with known risk factors for kidney disease.

The Primary Blood Test for Kidney Disease: eGFR and Creatinine

According to NHS guidance, the main test for kidney disease is a blood test. Specifically, it measures the level of creatinine — a waste product produced by normal muscle activity — in the bloodstream. Healthy kidneys continuously filter creatinine out of the blood and excrete it in urine. When the kidneys’ filtering capacity declines, creatinine builds up in the blood — and this rise in serum creatinine is the core signal that something is wrong.

A single creatinine result is informative but limited on its own, because creatinine levels vary naturally with muscle mass, age, sex, and diet. To make the result more clinically meaningful, UK laboratories automatically calculate the estimated glomerular filtration rate (eGFR) alongside every creatinine measurement, using the CKD-EPI (2009) formula approved by NICE. The eGFR represents an estimate of how many millilitres of blood the kidneys are filtering per minute per 1.73 square metres of body surface area.

According to Kidney Research UK, an eGFR of 90ml/min or above is within the normal range. A value below 60ml/min, if sustained across two separate tests at least 90 days apart, indicates chronic kidney disease. An eGFR of 15 or below may indicate kidney failure, requiring immediate medical assessment. It is important not to over-interpret a single mildly reduced eGFR — the UK Kidney Association notes that borderline values just below 60 should prompt repeat testing rather than immediate alarm, and that an eGFR of 60 to 89 is considered normal in the absence of any other markers of kidney damage.

Factors That Can Affect eGFR Accuracy

The eGFR formula incorporates creatinine alongside age and sex — but it has recognised limitations. People with very high muscle mass (such as bodybuilders) may have naturally elevated creatinine and therefore a falsely low eGFR. Conversely, those with very low muscle mass — the elderly or those with muscle-wasting conditions — may have a falsely reassuring eGFR despite meaningful kidney impairment. Where clinical uncertainty exists, cystatin C — an alternative kidney marker produced at a constant rate regardless of muscle mass — can be used to supplement or confirm the eGFR result, though it is not yet widely available in all UK settings. Patients are also advised to avoid eating red meat in the 12 hours before an eGFR blood test, as cooked meat temporarily raises creatinine levels and can affect the result.

The Second Key Marker: Albumin-to-Creatinine Ratio (ACR)

Blood creatinine and eGFR assess the kidneys’ filtering capacity — but they do not capture another critical aspect of kidney health: whether the kidneys are retaining protein as they should. Healthy kidneys act as a selective filter, keeping large molecules like albumin (a protein) in the bloodstream while excreting waste. When the kidneys are damaged, albumin leaks into the urine — a condition called albuminuria or proteinuria — which can appear many years before eGFR begins to decline.

The albumin-to-creatinine ratio (ACR) is measured from a urine sample rather than a blood test, but it is an essential companion to the eGFR in assessing kidney health. The UK Kidney Association states that urinary albumin leak may be the very first sign of kidney disease for many patients — particularly those with diabetes — and can precede a detectable fall in eGFR by years. According to Kidney Care UK, an ACR below 3mg/mmol requires no further action, a result of 3 to 70mg/mmol warrants a repeat test within three months, and above 70mg/mmol indicates significant proteinuria requiring prompt clinical assessment.

Together, the eGFR and ACR form the basis of the UK and international CKD staging system — the KDIGO G and A classification — which places patients on a grid from G1A1 (mildest) to G5A3 (most severe), guiding clinical decisions about monitoring frequency, treatment, and specialist referral.

Other Blood Markers That Support Kidney Disease Assessment

Beyond creatinine and eGFR, a comprehensive kidney health blood panel can reveal several additional features that are relevant to kidney disease diagnosis and management:

Urea

Urea is another waste product filtered by the kidneys. Elevated blood urea, alongside raised creatinine, strengthens the picture of impaired kidney function. It is worth noting that urea can also be elevated by dehydration or a high-protein diet, so it is interpreted in context rather than in isolation.

Electrolytes — Sodium, Potassium, Bicarbonate

The kidneys regulate the balance of electrolytes in the blood. As kidney function declines, sodium and potassium levels can become dysregulated, and bicarbonate may fall — producing metabolic acidosis. Abnormalities in these markers, particularly hyperkalaemia (raised potassium), can have serious cardiac consequences and are closely monitored in CKD management.

Full Blood Count

Anaemia is a common consequence of CKD. The kidneys produce erythropoietin, a hormone that stimulates red blood cell production. When kidney function falls, erythropoietin production declines, leading to a normochromic, normocytic anaemia that contributes significantly to the fatigue and breathlessness of advanced CKD.

Phosphate and Calcium

The kidneys play a central role in calcium-phosphate balance and vitamin D activation. In CKD, phosphate tends to rise while calcium and active vitamin D fall — disrupting bone metabolism and cardiovascular health. These markers are closely monitored from Stage 3 CKD onwards.

Parathyroid Hormone (PTH)

Secondary hyperparathyroidism — where the parathyroid glands overproduce PTH in response to low calcium and high phosphate — is a common complication of CKD that contributes to bone disease. PTH is measured as part of the metabolic monitoring of patients with established CKD.

A patient seen at our Birmingham clinic — a woman in her late fifties with well-controlled type 2 diabetes — attended for a routine health review. She had no kidney symptoms. A comprehensive private blood test identified a mildly elevated creatinine and an eGFR of 58ml/min. Repeat testing three months later confirmed a sustained eGFR below 60 alongside a mildly raised ACR — consistent with Stage 3A CKD. Early identification allowed her to start appropriate management promptly, including medication review and lifestyle modifications, significantly reducing her risk of further progression.

Who Should Be Tested for Kidney Disease?

Given that CKD is so often asymptomatic in its early stages, proactive testing is especially important for those with elevated risk. The NHS and NICE recommend regular kidney function monitoring for people with:

• Type 1 or type 2 diabetes
• High blood pressure (hypertension)
• Cardiovascular disease — heart failure, previous heart attack, or stroke
• A family history of kidney disease or inherited kidney conditions such as polycystic kidney disease
• Recurrent kidney infections or a history of kidney stones
• Obesity — a recognised independent risk factor for CKD progression
• Regular long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen
• Systemic autoimmune conditions such as lupus or vasculitis

For anyone in these categories, annual kidney function testing — at a minimum — is clinically prudent. If you have not had a kidney function test recently, or if you are outside NHS-registered GP care and would like a comprehensive assessment, a private blood test provides a straightforward and efficient way to understand your baseline kidney health.

Symptoms That Should Prompt Urgent Testing

While early kidney disease is often silent, more advanced kidney impairment can produce a range of symptoms that should always prompt prompt GP assessment:

• Persistent fatigue or breathlessness not explained by another condition
• Ankle, foot, or leg swelling
• Changes in urination — going more or less frequently, foamy or frothy urine indicating protein, or blood in the urine
• Persistent itching without a clear skin cause
• Nausea, reduced appetite, or unintentional weight loss
• Difficulty concentrating or a persistent sense of mental fogginess
• High blood pressure that is new or increasingly difficult to control
• Muscle cramps, particularly at night

If any of these resonate alongside risk factors for kidney disease, please do not wait. A face-to-face GP consultation at The Private GP in Birmingham gives you access to a GMC-registered doctor who will assess your symptoms thoroughly, arrange same-day kidney function testing, and act promptly on any findings — without the delay of an NHS appointment. Same-day appointments are available. Book today.

What Happens After an Abnormal Kidney Blood Test?

If an eGFR below 60 or a raised ACR is found, the next step is confirmation rather than immediate alarm. According to Kidney Care UK and the South and West NHS Devon CKD guidance, a single abnormal result prompts a repeat test within two to three weeks to rule out acute kidney injury or transient changes. If the second test confirms the findings, a formal CKD diagnosis is made and an appropriate management plan is established.

Further investigations may include a urine dipstick for haematuria (blood in the urine), an ultrasound to assess kidney structure, and review of any medications that may be affecting kidney function — particularly NSAIDs, certain antibiotics, and ACE inhibitors or ARBs in specific contexts. Depending on the CKD stage and ACR category, specialist nephrology referral may be arranged. The UK Kidney Association guidance notes that deteriorating renal function requires rapid assessment, and that referral to or discussion with a specialist is usual from Stage 3B (eGFR 30–44ml/min) onwards.

How a Private Blood Test Can Help

At The Private GP in Birmingham, our private blood testing service includes a comprehensive renal profile covering creatinine, eGFR, urea, electrolytes, full blood count, and more — with same-day results and clinical interpretation by a GMC-registered GP. If an eGFR blood test is what you specifically need, we can arrange this quickly and efficiently, with results explained clearly in the context of your health history and risk factors.

Whether you have risk factors for kidney disease, have received a borderline result you want to understand better, or simply want a clear picture of your kidney health, we are here to provide the answers you need — promptly, professionally, and without unnecessary waiting. Early identification of kidney disease is one of the most meaningful steps you can take to protect your long-term health.

Frequently Asked Questions

• What does an eGFR blood test show?

The eGFR (estimated glomerular filtration rate) is calculated from your blood creatinine level alongside your age and sex, using the NICE-approved CKD-EPI formula. It estimates how many millilitres of blood your kidneys are filtering per minute — a direct measure of kidney function. An eGFR above 90ml/min is normal. A value below 60ml/min, confirmed on two tests at least 90 days apart, is diagnostic of chronic kidney disease. Our private eGFR blood test in Birmingham provides same-day results with full GP interpretation.

• Can a normal blood test rule out kidney disease?

Not entirely. A normal creatinine and eGFR means kidney filtering capacity is adequate at the time of testing — but early kidney damage can be present without any change in eGFR if the kidneys are compensating. Albumin in the urine (measured via the ACR urine test) can appear years before the eGFR starts to fall, particularly in diabetes and hypertension. A full kidney assessment should include both a blood test and a urine ACR for the most complete picture.

• How quickly can kidney disease be detected with a blood test?

A blood creatinine and eGFR result is available within hours of the sample being taken. At The Private GP, results from a private blood test are typically available the same day, with a GP on hand to interpret the findings and advise on any necessary next steps. If an abnormal result requires confirmation, a repeat test is usually arranged within two to three weeks.

• What level of eGFR should I be worried about?

An eGFR below 60ml/min on two tests at least 90 days apart indicates chronic kidney disease and warrants clinical management. An eGFR of 30 to 44ml/min (Stage 3B) represents a significantly elevated risk of both kidney failure and cardiovascular disease, and specialist input is usually recommended. An eGFR at or below 15ml/min may indicate kidney failure and requires immediate medical attention. A single borderline result between 50 and 60 should not be over-interpreted — repeat testing and clinical context matter considerably.

• Should I get a kidney function test if I have diabetes or high blood pressure?

Yes — and regularly. Both diabetes and hypertension are the most common causes of CKD in the UK, and NICE recommends annual kidney function monitoring for all people with these conditions. Kidney damage from diabetes and hypertension develops gradually and silently, which means regular testing is the only reliable way to detect it early enough to slow or prevent further progression. A private full health check-up at The Private GP includes kidney function assessment alongside a comprehensive range of other health markers, with same-day results and GP review.

Ramadan presents a genuine practical question for anyone who needs a blood test during the holy month. The fasting period — which runs from dawn (Fajr) to sunset (Maghrib) — prohibits eating, drinking, and for some interpretations, the administration of anything into the body. Understanding how this intersects with clinical blood testing is important both for managing your health and for respecting your religious practice.

The reassuring answer is that for many blood tests, having blood drawn during the fasting hours of Ramadan is not only clinically acceptable but can, in some cases, actually align well with the requirements of fasting-based tests. However, there are important nuances depending on which tests you need, how long into the fast you are, and your individual health circumstances.

Does a Blood Draw Break the Fast?

This is the first question many patients ask, and the answer varies depending on individual scholarly interpretation. The majority view among Islamic scholars is that a blood draw for medical purposes does not break the fast. Blood taken for diagnostic testing is not ingested, and the intention behind the act is medical rather than nourishment — a distinction recognised within Islamic jurisprudence (fiqh).

However, individual interpretations differ, and some scholars hold that a blood draw — particularly a larger volume — may affect the validity of the fast. If this is a concern for you, it is worth consulting with your imam or a scholar you trust before your appointment. What is important to note from a clinical perspective is that the act of venepuncture itself, and the small volume of blood removed, has no meaningful physiological effect on the body’s fasting state.

How Does Ramadan Fasting Affect Blood Test Results?

From a purely clinical standpoint, Ramadan fasting is a form of intermittent fasting — one that typically involves abstaining from food and water for twelve to sixteen hours, depending on the time of year. This has measurable effects on several blood markers, some of which are clinically meaningful and some of which are negligible.

Blood Glucose

After a prolonged fast, blood glucose levels naturally decrease as the body shifts from glucose-based to fat-based energy metabolism. This is a normal physiological response, but it means that a fasting glucose test taken during Ramadan may reflect a lower reading than your habitual baseline. For routine glucose screening in a healthy person, this is unlikely to be clinically significant. For someone being monitored for diabetes or insulin resistance, the timing and context of the test should be discussed with your clinician.

Cholesterol and Lipids

Research on the effect of Ramadan fasting on lipid profiles shows mixed results. Some studies suggest that prolonged fasting leads to a modest reduction in total cholesterol and LDL, with a slight rise in HDL — a broadly favourable pattern. Triglycerides tend to decrease with sustained fasting. For a fasting cholesterol panel, which routinely requires eight to twelve hours of fasting, blood drawn during the Ramadan fast is likely to meet the standard fasting requirement with time to spare, and results will generally be interpretable as reliable.

Full Blood Count

A full blood count is not significantly affected by fasting in the short term. Haemoglobin, white cell count, platelet levels, and related markers reflect longer-term physiological states rather than what has or has not been consumed in the preceding hours. A blood count drawn during Ramadan fasting hours is clinically reliable for these purposes.

Dehydration Markers

This is where Ramadan fasting introduces a more meaningful clinical consideration. Abstaining from water as well as food — particularly during longer summer fasting hours — can lead to mild dehydration. This raises the concentration of several markers in the blood, including urea, creatinine, and sodium. Kidney function tests and electrolyte panels taken at the end of a long fast without water may show readings that appear mildly elevated, not because of underlying disease but because of the concentrated state of the blood.

If kidney function or electrolytes are part of your panel — including an eGFR test — your clinician should be aware that you have been fasting without water so that the result can be interpreted in the right context.

Inflammatory Markers and Thyroid Function

Neither CRP nor thyroid function markers are significantly affected by short-term fasting. Tests for these markers taken during Ramadan fasting hours are reliable and do not need to be delayed or rescheduled on that basis.

The Best Time to Book Your Blood Test During Ramadan

If you want to minimise both the religious uncertainty around the blood draw and the potential clinical impact of dehydration, the most practical approach is to book your appointment shortly after Iftar — the evening meal at sunset — or in the window before Suhoor (the pre-dawn meal), once you have had the opportunity to eat and drink.

This approach has several advantages. You will have broken your fast, allowing you to hydrate properly before attending. The physiological effects of dehydration will have had time to resolve. And for any tests that do not require fasting, your results will reflect a normal hydrated state rather than the concentrated blood chemistry of a prolonged fast without water.

For tests that specifically require fasting — such as a fasting glucose or lipid panel — the Ramadan fast itself may satisfy the requirement, provided your clinician is aware of the context and the timing of your last meal (Suhoor).

Important Considerations for Patients With Existing Health Conditions

For most healthy adults, Ramadan fasting and routine blood testing are entirely compatible with careful timing and clinical awareness. However, for patients managing chronic conditions — particularly diabetes, kidney disease, cardiovascular conditions, or thyroid disorders — additional thought is needed.

• Fasting with diabetes carries specific risks, including hypoglycaemia, and medication timing during Ramadan should be reviewed with your GP before the month begins rather than managed reactively. Blood glucose testing during Ramadan needs to be interpreted alongside your medication schedule and eating pattern.
• Kidney disease. Patients with reduced kidney function are more susceptible to dehydration-related complications during prolonged fasting without water. Blood tests assessing kidney function should ideally be taken in a well-hydrated state; if this is not possible, your clinician should factor the fasting context into their interpretation.
• Cardiovascular conditions. Fasting can affect blood pressure, heart rate, and medication efficacy. If you are due a health review or blood panel during Ramadan, discuss the timing with your GP so that any medication adjustments are made in advance.

A Clinician Who Understands Your Needs

Managing your health during Ramadan should not mean choosing between your religious practice and your clinical care. At The Private GP in Birmingham, our doctors are experienced in working with patients across a wide range of health backgrounds and personal circumstances. Whether you need a private blood test timed to fit around your fast, or a consultation to discuss how Ramadan may interact with a condition you are managing, we offer flexible same-day appointments with the time and attention your situation deserves.

Frequently Asked Questions

• Does having blood taken break the Ramadan fast?

The majority scholarly view is that a blood draw for medical purposes does not invalidate the fast, as it is not ingested and the intention is clinical rather than nourishment. However, interpretations vary, and if this is a concern for you, it is worth seeking guidance from a scholar or imam whose opinion you trust before your appointment.

• Is fasting blood drawn during Ramadan accurate for cholesterol tests?

Generally yes. A fasting cholesterol panel requires eight to twelve hours of fasting, which the Ramadan fast easily satisfies. Results taken during the fasting hours are typically reliable for lipid assessment, provided your clinician is aware of the context.

• Can dehydration during Ramadan affect blood test results?

Yes, and this is the most clinically significant consideration for Ramadan fasting. Abstaining from water during long fasting hours can concentrate the blood, causing kidney function markers, urea, and electrolytes to appear mildly elevated. Always inform your clinician that you have been fasting without water so that results can be interpreted in the correct context.

• What is the best time to have a blood test during Ramadan?

For most people, shortly after Iftar — once you have eaten and rehydrated — is the most practical and clinically sound time to have a non-fasting blood test. For fasting tests, the Ramadan fast itself may satisfy the requirement; discuss the timing with your clinician when booking.

• Should I tell my doctor I am fasting during Ramadan before my blood test?

Yes, always. Knowing that you are observing Ramadan fasting — including abstaining from water — allows your clinician to interpret your results accurately, choose the most appropriate timing for your appointment, and factor your fasting pattern into any medication or health management advice. There is no need to delay or avoid testing during Ramadan with the right clinical support in place.

Book a Blood Test in Birmingham

If you need a blood test during Ramadan and want to ensure the timing and context are right for both your health and your fast, The Private GP offers same-day private blood tests in Birmingham with flexible appointments and results reviewed directly with a doctor. We will work with you to find an approach that fits your needs — clinically and personally.